Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17932910 | 1.00 | TSHR (0.40) | TSHRCYP3A4CA2MEN1KMT2A | |
| SCHEMBL4431471 | 1.00 | TSHR (0.40) | TSHRCYP3A4CA2MEN1KMT2A | |
| SCHEMBL4422489 | 0.97 | TSHR (0.39) | TSHRCYP3A4CA2MEN1KMT2A | |
| SCHEMBL10180983 | 0.97 | TSHR (0.39) | TSHRCYP3A4CA2MEN1KMT2A | |
| SCHEMBL9146882 | 0.97 | TSHR (0.39) | TSHRCYP3A4CA2MEN1KMT2A | |
| SCHEMBL11995932 | 0.93 | MEN1 (0.42) | TSHRCYP3A4CA2MEN1KMT2A | |
| SCHEMBL4424020 | 0.93 | TSHR (0.40) | TSHRCYP3A4CA2MEN1KMT2A | |
| SCHEMBL987113 | 0.93 | TSHR (0.40) | TSHRCYP3A4CA2MEN1KMT2A | |
| SCHEMBL11995937 | 0.93 | MEN1 (0.42) | TSHRCYP3A4CA2MEN1KMT2A | |
| SCHEMBL16598028 | 0.93 | MEN1 (0.42) | TSHRCYP3A4CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796655-B2 | Method for producing carbonate compound | ASAHI GLASS COMPANY, LIMITED (JP) | 2017-10-24 | — | — | US | disclosed |
| US-9796655-B2 | Method for producing carbonate compound | ASAHI GLASS COMPANY, LIMITED (JP) | 2017-10-24 | — | — | US | disclosed |
| US-20150284314-A1 | METHOD FOR PRODUCING CARBONATE COMPOUND | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-10-08 | — | — | US | disclosed |
| US-20150284314-A1 | METHOD FOR PRODUCING CARBONATE COMPOUND | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-10-08 | — | — | US | disclosed |
| US-8956768-B2 | Nonaqueous electrolyte comprising one or more hydrofluoroethers and one or more non-fluoroethers, and a secondary cell containing the nonaqueous electrolyte | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8956768-B2 | Nonaqueous electrolyte comprising one or more hydrofluoroethers and one or more non-fluoroethers, and a secondary cell containing the nonaqueous electrolyte | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20120214073-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERIES, AND SECONDARY BATTERY | ASAHI GLASS COMPANY, LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20120214073-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERIES, AND SECONDARY BATTERY | ASAHI GLASS COMPANY, LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| EP-2450998-A1 | ELECTROLYTIC SOLUTION FOR CHARGEABLE DEVICE, ELECTROLYTIC SOLUTION FOR LITHIUM ION SECONDARY BATTERY, AND SECONDARY BATTERY | Asahi Glass Company, Limited (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20120107701-A1 | ELECTROLYTE SOLUTION FOR CHARGEABLE DEVICE, ELECTROLYTE SOLUTION FOR LITHIUM ION SECONDARY BATTERY, AND SECONDARY BATTERY | ASAHI GLASS COMPANY, LIMITED (JP) | 2012-05-03 | — | — | US | disclosed |
| US-20120107701-A1 | ELECTROLYTE SOLUTION FOR CHARGEABLE DEVICE, ELECTROLYTE SOLUTION FOR LITHIUM ION SECONDARY BATTERY, AND SECONDARY BATTERY | ASAHI GLASS COMPANY, LIMITED (JP) | 2012-05-03 | — | — | US | disclosed |
| US-20110020700-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY CELL, AND SECONDARY CELL | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-01-27 | — | — | US | disclosed |
| US-20110020700-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY CELL, AND SECONDARY CELL | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284314-A1 | METHOD FOR PRODUCING CARBONATE COMPOUND | CA9, CA11, CA2 | TSHR 3961/4885CYP3A4 966/4885CA2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.